Human cells build protein cages to trap invading Shigella
In research on the never-ending war between pathogen and host, scientists at the Pasteur Institute in Paris have discovered a novel defensive weapon, a cytoskeletal protein called septin, that humans cells deploy to cage the invading Shigella bacteria that cause potentially fatal human diarrhea, according to a presentation at the American Society for Cell Biology Annual Meeting in Denver.
Pascale Cossart, Ph.D., and Serge Mostowy, Ph.D., reported that the septin cages not only targeted the pathogens for degradation by autophagy, the cell's internal garbage disposal system, but also prevented the Shigella bacteria from spreading to other cells by impeding the pathogens' access to actin, a different component of the cell skeleton.
Shigella requires actin to rocket around the host cell before punching into an adjacent cell, said the Pasteur researchers, who made their discovery in human cells grown in culture in the laboratory.
First discovered in yeast as rings that pinch off dividing cells, septins are Guanosine-5'-triphosphate (GTP)-binding proteins that are integral to a cell's dynamic skeleton. Cossart, a Howard Hughes Medical Institute (HHMI) investigator, and Mostowy continue to investigate the properties of the individual septins, which total 14 in humans, to understand how they associate with other proteins as parts of complex nano-machines.
Before their studies revealed septin's new role in innate immunity, Cossart and Mostowy said that the cytoskeletal protein already was implicated in the pathogenesis of many human disorders including leukemia and colon cancer as well as Parkinson's and Alzheimer's diseases.
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Applied Biosystems Announces Joint Research Protocol with the NCI Cohort Consortium in Study of Breast and Prostate Cancer
Codexis Appoints Singapore Laboratories Managing Director
Indian_gooseberry
Database AnimalTestInfo: German initiative for more transparency in animal experiments - Information on the purpose of animal experiments and the expected levels of distress caused to animals now provided to the public

B 35 | Freezers | FRYKA Kältetechnik
